-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Dolphin Congratulates Shore Fire Media and Its Clients on 20 GRAMMY(R) Nominations, Including 10 Best Album Nods Across Diverse Genres
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
5E Advanced Materials Highlights Commercial Momentum in First Month as an Operating Borates Producer
-
Trout CPA Expands Partner Leadership with Michael Carr and Dan Lerew
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Jumia Reports Third Quarter 2026 Results
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
What to Do When Two Households Become One
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
Pres. Trump's Chance to Fix DEA's Marijuana Policy Failures: Rescheduling?
DEA Administrator Terrance Cole has also signaled a tough line: "Everybody knows my stance on marijuana after 30 plus years in law enforcement, so don't even ask!" However, with all due respect to law enforcement, you can't fight a disease with a badge.
MMJ is developing FDA regulated medicine, not an illicit substance. We are the science, and our mission is to treat patients, not to police a plant." Duane Boise, CEO MMJ International Holdings.
WASHINGTON, DC / ACCESS Newswire / August 19, 2025 / For too long, the DEA has written rules, then ignored them. It has promised science, then sidelined it. Patients with Huntington's disease and Multiple Sclerosis have been told to wait, while recreational markets flourish outside federal control.
President Trump's consideration of rescheduling marijuana is the first serious chance in decades to break this cycle. The challenge now is ensuring that reform does not just enrich Big Weed - but instead delivers on the promise of real medicine.

That's the difference. That's why MMJ matters.
A Risk Worth Facing Carefully
President Trump is weighing whether to reschedule marijuana at the federal level. Critics warn this could hand a windfall to the $33 billion cannabis industry, which has cloaked itself in medical rhetoric while chasing profits through high-potency recreational products. They are right to be skeptical: today's marijuana bears little resemblance to the mild 5% THC plant of decades ago. Gummies, vapes, and concentrates now approach 99% THC, raising real risks of psychosis, schizophrenia, and bipolar disorder, as large-scale studies in Denmark and Sweden have shown.
Trump, who never drank or smoked after losing his brother Fred Jr. to alcoholism, understands personally the devastation of addiction. Newly confirmed DEA Administrator Terrance Cole has also signaled a tough line, writing bluntly: "Everybody knows my stance on marijuana after 30 plus years in law enforcement, so don't even ask!" His priorities - fentanyl, cartels, and violent drug trafficking - point clearly away from Big Weed's agenda.
But here's the crucial distinction: not all marijuana is the same, and not all companies are Big Weed.
The Evidence of Benefit Cannot Be Ignored
Yes, the risks are real. But so too are the thousands of patients who have long reported relief from cannabis.
Cancer patients use it to control nausea and pain.
MS patients to ease spasticity.
Children with epilepsy to reduce seizures.
These are not isolated stories - they represent a consistent pattern of strong anecdotal evidence suggesting cannabis compounds may hold therapeutic value.
The problem? Anecdotes are not enough. To separate myth from medicine, cannabis must be tested like any other drug - through rigorous, FDA-supervised clinical trials.
MMJ: From Anecdote to Medicine
This is where MMJ BioPharma is different. Unlike recreational marijuana companies or state dispensaries, MMJ has built a true pharmaceutical pathway:
Two FDA-approved INDs (Investigational New Drug applications): For Huntington's Disease and Multiple Sclerosis.
FDA Orphan Drug Designation: For Huntington's Disease.
DEA Schedule I analytical lab registration: Already in place and compliant.
Softgel Capsule Manufactured Under FDA Directives: MMJ has already produced a reproducible, final-dose form gel cap that meets the definition of medicine - not snake oil.
This capsule is not a dispensary product or a vape pen. It is a standardized, pharmaceutical grade medicine designed to be taken by patients under physician supervision. Reproducibility has been achieved - the cornerstone of real science. Now MMJ seeks to prove efficacy in FDA authorized human clinical trials.
DEA's Broken Promises
In 2020, the DEA pledged that new marijuana licenses would prioritize science: applicants would need bona fide FDA protocols, supply agreements with researchers, and the capacity to produce adequate quantities for trials.
Four years later, not one registrant has delivered. Some never planted a seed. Others produced trivial amounts. None filed with the FDA.
Meanwhile, the only company that meets DEA's published criteria - MMJ BioPharma, with FDA INDs, Orphan Designation, and a manufactured softgel capsule - remains stalled.
The Path Trump and Cole Can Take
The choice for President Trump and Administrator Cole is not between legalization and prohibition. It is between:
Big Weed's recreational profiteering that fuels addiction, psychosis, and chaos.
FDA-regulated, science-driven pharmaceutical research that could deliver safe, effective medicines to patients with no alternatives.
Trump and Cole can reject Big Weed while supporting MMJ's mission to turn anecdotal evidence into approved therapies. Patients with Huntington's and Multiple Sclerosis deserve more than dispensary "snake oil." They deserve real medicine, developed under federal law, proven through science.
Promises Made, Promises Not Kept - Until Now?
DEA has failed to live up to its own commitments. But with rescheduling now on the table, President Trump and Terrance Cole have the chance to make a historic course correction: to draw a clear line between recreational profiteering and pharmaceutical science, between snake oil and medicine.
That is the path forward. That is the fix. That is why MMJ matters.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-85832
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
A.Williams--AT